← Leaderboards
Ravi Amrit Madan
Massachusetts General Hospital
$1,203,094
Attributed
$2,406,187
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $611.6K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,406,187 · 1
By mechanism
U01$2,406,187 · 1
Top collaborators
- Mehmet Toner4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- E. Antonio Chiocca$34,514,665
- Mehmet Toner$56,861,630
- Stephanie Seminara$24,106,423
- Shyamala Maheswaran$4,911,288
- Daniel A. Haber$29,412,047
Others in their field
Other Rising Stars on “Frequencies”
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
- Jinsy Andrews · Columbia University Health Sciences$11,474,975
- Nancy Jean Sullivan · Boston University Medical Campus$7,541,758
- Jacob Sutton Coverstone · Neurovations$6,882,205
- Jennifer Lapek · Scripps Institution Of Oceanography$6,359,752
Research focus
FrequenciesBiopsyExtramural ActivitiesEzh2 GeneCancer CellCancer PatientBiopsy SpecimenAndrogen ReceptorExposure ToEvolutionCell SeparationClinical BiomarkersClinical CenterClinical DevelopmentClinical TrialsCollaborationsCollectionDesignDna AnalysisBloodDocetaxelCellsEvaluationFuture
Grant awards (4)
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer$611,570
U01 · FY2025 · CA
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer$591,227
U01 · FY2024 · CA
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer$592,252
U01 · FY2023 · CA
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer$611,138
U01 · FY2022 · CA